Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Antengene Corporation Limited (6996.HK)
Shanghai, CN
Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed its Phase I evaluation for chronic human viral infections. The company is also advancing ATG-019, a dual PAK4/NAMPT inhibitor targeting non-Hodgkin's lymphoma and advanced solid tumors, and ATG-017, an ERK1/2 inhibitor designed for treating advanced solid tumors and hematologic malignancies. Additionally, ATG-010 (selinexor) is a SINE compound that modulates XPO1. ATG-101, a bispecific PD-L1/4-1BB antibody, is in Phase I studies for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Completing its clinical-stage assets is ATG-008 (onatasertib), an orally delivered mTOR kinase inhibitor aimed at solid tumors exhibiting specific genetic alterations like NFE2L2, STK11, and RICTOR. In its earlier, pre-clinical research phase, Antengene is exploring ATG-037, a CD73 inhibitor for advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031, a CD24 antibody; ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Founded in 2016, the company maintains its headquarters in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.75% | +1.14% | -11.53% | +36.09% | -1.55% | +17.41% | +6.46% | +128.21% | -74.01% | -75.66% | -75.66% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+14.6% ★ Q4'25: +1,207.1% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+25.5% Q4'25: +55.9% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-174.8% Q4'25: -342.9% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-226.8% Q4'25: -240.8% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-144.0% Q4'25: -302.8% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+1.0% ★ Q4'25: +2.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.16× Q4'25: -0.56× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
28.77M
est: 6.14M (+368.8%)
|
160.14M
est: 203.76M (-21.4%)
|
67.31M
est: 271.40M (-75.2%)
|
91.95M
est: 95.27M (-3.5%)
|
105.34M
est: 130.05M (-19.0%)
|
691.40M
691.40M – 691.40M
+431.7% YoY
|
337.07M
337.07M – 337.07M
-51.2% YoY
|
340.44M
340.44M – 340.44M
+1.0% YoY
|
| EBITDA |
-614.32M
est: -3.68M (-16,584.4%)
|
-866.06M
est: -122.26M (-608.4%)
|
-550.31M
est: -162.84M (-238.0%)
|
-348.82M
est: -95.27M (-266.2%)
|
-221.25M
est: -130.05M (-70.1%)
|
-691.40M
-691.40M – -691.40M
-431.7% YoY
|
-337.07M
-337.07M – -337.07M
+51.2% YoY
|
-340.44M
-340.44M – -340.44M
-1.0% YoY
|
| EBIT |
-618.24M
est: -3.68M (-16,691.1%)
|
-878.93M
est: -122.26M (-618.9%)
|
-580.29M
est: -162.84M (-256.4%)
|
-364.74M
est: -95.27M (-282.9%)
|
-238.91M
est: -130.05M (-83.7%)
|
-691.40M
-691.40M – -691.40M
-431.7% YoY
|
-337.07M
-337.07M – -337.07M
+51.2% YoY
|
-340.44M
-340.44M – -340.44M
-1.0% YoY
|
| Net Income |
-655.53M
est: -671.09M (+2.3%)
|
-601.49M
est: -296.03M (-103.2%)
|
-581.18M
est: -383.23M (-51.7%)
|
-319.25M
est: -338.11M (+5.6%)
|
-239.13M
est: -237.92M (-0.5%)
|
267.52M
267.52M – 267.52M
+212.4% YoY
|
-75.74M
-75.74M – -75.74M
-128.3% YoY
|
-119.30M
-119.30M – -119.30M
-57.5% YoY
|
| SGA |
237.40M
est: 23.98M (+890.2%)
|
522.45M
est: 796.13M (-34.4%)
|
340.80M
est: 1.06B (-67.9%)
|
179.99M
est: 381.49M (-52.8%)
|
156.63M
est: 520.77M (-69.9%)
|
2.77B
2.77B – 2.77B
+431.7% YoY
|
1.35B
1.35B – 1.35B
-51.2% YoY
|
1.36B
1.36B – 1.36B
+1.0% YoY
|
| EPS |
-1.05
est: -1.08 (+2.9%)
|
-0.97
est: -0.48 (-103.3%)
|
-0.94
est: -0.62 (-52.2%)
|
-0.51
est: -0.54 (+5.5%)
|
-0.38
est: -0.38 (0.0%)
|
0.43
0.43 – 0.43
+212.4% YoY
|
-0.12
-0.12 – -0.12
-128.3% YoY
|
-0.19
-0.19 – -0.19
-57.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 154.6K | 0.65% |
| 2 | State Street SPDR S&P China ETF GXC | 0.01% | 32.8K | 0.59% |
| 3 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 709.5K | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jay Mei | Founder, Chairman & Chief Executive Officer | 14M | — |
| Donald Andrew Lung | Chief Financial Officer & Executive Director | 4M | male |
| Hou Bing | Chief Scientific Officer | — | — |
| Rui Guo | Executive Officer | — | female |
| Shimin Sun | Corporate Vice President and Head of Clinical Enabling Functions & Operational Excellence | — | female |
| Thomas Karalis | Corporate Vice President & Head of Asia Pacific Region | — | male |
| Wai Chiu Wong | Joint Company Secretary | — | male |
| Yang Cao | Joint Company Secretary | — | male |
| Dirk Hoenemann | Vice President and Head of Medical Affairs for APAC & Early Clinical Development | — | — |
| Yiteng Liu | Chief Operating Officer | — | male |
| Eitan Liu | Chief Operating Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6996.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
